Ir.crinetics.com
Crinetics Pharmaceuticals
WEBTitle: Once Daily Oral Atumelnant (CRN04894) Induces Rapid and Profound Reductions of Androstenedione and 17-hydroxyprogesterone in Participants with Classical Congenital Adrenal Hyperplasia: Initial Results from a 12-Week, Phase 2, Open-Label Study
Actived: 7 days ago
Crinetics Pharmaceuticals
WEBSAN DIEGO, July 29, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it would receive up to approximately …
Crinetics Pharmaceuticals
WEBSAN DIEGO, Aug. 13, 2019 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial results for the quarter ended June 30, …
Crinetics Pharmaceuticals
WEBSAN DIEGO – July 13, 2017 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, announced today that it was awarded a Phase IIB Small Business Innovation Research (SBIR) grant of up to $2.8 million from the National Institute of Diabetes and Digestive and Kidney Diseases …
Crinetics Pharmaceuticals
WEBSAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today the addition of corporate, clinical, and legal advisers as the company prepares for the clinical development of its pipeline of first- and best-in-class medicines.. Matt Fust will serve as …
Corporate Presentation
WEBDeep roots in endocrinology World-class in-house R&D 4 | Commitment to transforming people’s lives Purposely crafted medicines = The Crinetics Way: Endocrinology for Health Paltusotine is an investigational drug candidate currently in clinical studies
Crinetics Pharmaceuticals
WEBSAN DIEGO – June 21, 2018 – Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today announced that it has been awarded up to approximately $3.2 million in Small Business …
Crinetics Pharmaceuticals
WEBPresentation details: (OR12) Inhibition of Basal and ACTH-Stimulated Cortisol Secretion in Humans Using an Oral, Nonpeptide ACTH Antagonist (CRN04894) Sunday, June 12, 2022 11:15 a.m. - 11:30 a.m. ET Oral Session; A404-A405 (PSUN304) CRN04777, an Oral, Nonpeptide SST5-selective Somatostatin Agonist Dose Dependently Suppresses Basal …
Crinetics Pharmaceuticals
WEBSAN DIEGO – March 7, 2018 – Crinetics Pharmaceuticals, Inc., a rare disease therapeutics company focused on endocrine disorders and endocrine-related cancers, today announced that Scott Struthers, Ph.D., founder and chief executive officer, will present at the Cowen and Company 38th Annual Health Care Conference on Wednesday, March 14, 2018 at …
Crinetics Pharmaceuticals Awarded National Institutes of Health …
WEBSAN DIEGO — February 7, 2009 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a Phase I Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop G protein-coupled receptor (GPCR) biosensors for drug discovery applications.The grant supports the …
Crinetics Pharmaceuticals
WEBSAN DIEGO — September 3, 2013 — San Diego-based Crinetics Pharmaceuticals announced today that it has been awarded a $2.2MM Phase II Small Business Innovation Research (SBIR) grant from the National Institutes of Health (NIH) to develop novel drugs for the treatment of pituitary tumors.
Crinetics Pharmaceuticals
WEBSAN DIEGO , Aug. 30, 2018 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq:CRNX), a clinical stage pharmaceutical company focused on the discovery, development and commercialization of novel therapeutics for rare endocrine diseases and endocrine-related tumors, today reported financial
Crinetics Pharmaceuticals to Present at the 4th Annual Evercore ISI
WEBCrinetics Pharmaceuticals management will participate in a fireside chat and one-on-one investor meetings at the 4th Annual Evercore ISI HealthCONx Conference, which is taking place virtually November 30, 2021 through December 2, 2021.
Crinetics Pharmaceuticals
WEBSAN DIEGO – April 27, 2015 – Crinetics Pharmaceuticals (“Crinetics”), an innovative therapeutics company focused on endocrine diseases and cancers, announced today that it has been awarded Phase I of a Fast-Track Small Business Innovation Research (SBIR) grant of up to $2.7MM from the National
40th Annual J.P. Morgan Health Care Conference
WEBJan 12, 2022 at 4:30 PM EST. Scott Struthers, Ph.D., founder & CEO of Crinetics, will provide a company update at the 40th annual J.P. Morgan Healthcare Conference on Wednesday, January 12th at 4:30 PM Eastern Time / 1:30 PM Pacific Time. A live audio webcast of Dr. Struthers’ presentation may be accessed on the Events page of the …
Crinetics Pharmaceuticals
WEBWebinar Being Held on August 8, 2023 at 12:00 p.m. Eastern Time. SAN DIEGO, July 31, 2023 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that it will host a Key Opinion Leader (KOL) webinar on August 8, 2023 at 12:00 pm Eastern Time, featuring presentations by KOLs Beverly MK Biller M.D. and Karen JP …
Top Categories
Popular Searched
› Blink health online ordering
› How unhealthy is raising canes
› Is nevada a poor health country
› Generic tadalafil blink health
Recently Searched
› Cascade mental health tukwila wa
› Cornerstone healthcare training academy
› Er health acronym on pay stub
› Cha everett family health center
› Psychiatric mental health services usa
› Mentally healthy schools website
› Rhody health partners expansion
› Kettering health gyn hamilton